Justin Koteff

573 total citations
9 papers, 381 citations indexed

About

Justin Koteff is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Justin Koteff has authored 9 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 5 papers in Virology and 3 papers in Epidemiology. Recurrent topics in Justin Koteff's work include HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). Justin Koteff is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). Justin Koteff collaborates with scholars based in United Kingdom, United States and Italy. Justin Koteff's co-authors include Amanda Peppercorn, Ivy Song, Julie Borland, T Koshiba, Shuguang Chen, Stephen C. Piscitelli, Romina Quercia, Katy H. P. Moore, Marty St. Clair and Daniel R. Kuritzkes and has published in prestigious journals such as British Journal of Clinical Pharmacology, JAIDS Journal of Acquired Immune Deficiency Syndromes and AIDS Research and Human Retroviruses.

In The Last Decade

Justin Koteff

9 papers receiving 373 citations

Peers

Justin Koteff
Magda Opsomer Belgium
Clotilde Le Tiec France
Miguel Goicoechea United States
L. Trentini Italy
Steve West United States
Michael L. Lim United States
Gema González‐Pardo Spain
Lloyd Curtis United States
Antonio Antela Spain
Magda Opsomer Belgium
Justin Koteff
Citations per year, relative to Justin Koteff Justin Koteff (= 1×) peers Magda Opsomer

Countries citing papers authored by Justin Koteff

Since Specialization
Citations

This map shows the geographic impact of Justin Koteff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin Koteff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin Koteff more than expected).

Fields of papers citing papers by Justin Koteff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin Koteff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin Koteff. The network helps show where Justin Koteff may publish in the future.

Co-authorship network of co-authors of Justin Koteff

This figure shows the co-authorship network connecting the top 25 collaborators of Justin Koteff. A scholar is included among the top collaborators of Justin Koteff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin Koteff. Justin Koteff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Giambenedetto, Simona Di, Antonella d’Arminio Monforte, José L. Casado, et al.. (2021). HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. Infectious Diseases and Therapy. 10(4). 2051–2070. 41 indexed citations
2.
Eron, Joseph J., Chien‐Ching Hung, Jean‐Guy Baril, et al.. (2020). Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes. 84(1). 60–65. 15 indexed citations
3.
Boffito, Marta, Laura Waters, Pedro Cahn, et al.. (2019). Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. AIDS Research and Human Retroviruses. 36(1). 13–18. 28 indexed citations
4.
Rios, Patricia, et al.. (2019). 1329. Experiences and Emotional Challenges of Antiretroviral Treatment (ART)—Findings from the Positive Perspectives Study. Open Forum Infectious Diseases. 6(Supplement_2). S481–S481. 13 indexed citations
5.
Eron, Joseph J., Chien‐Ching Hung, Jean‐Guy Baril, et al.. (2019). Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies. Journal of Infection and Public Health. 12(2). 296–296. 3 indexed citations
6.
Quercia, Romina, Carlo Federico Perno, Justin Koteff, et al.. (2018). Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 78(2). 125–135. 65 indexed citations
7.
Young, Benjamin, Bruno Spire, Marvelous Muchenje, et al.. (2017). Patient Experience and Views on Antiretroviral Treatment—Findings from the Positive Perspectives Survey. Open Forum Infectious Diseases. 4(suppl_1). S431–S432. 2 indexed citations
8.
Trottier, Benoît, Jordan E. Lake, Cynthia Brinson, et al.. (2016). Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study. Antiviral Therapy. 22(4). 295–305. 82 indexed citations
9.
Koteff, Justin, Julie Borland, Shuguang Chen, et al.. (2012). A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para‐aminohippurate clearance in healthy subjects. British Journal of Clinical Pharmacology. 75(4). 990–996. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Magda Opsomer Breakdown of academic impact, for papers by Clotilde Le Tiec Breakdown of academic impact, for papers by Miguel Goicoechea Breakdown of academic impact, for papers by L. Trentini Breakdown of academic impact, for papers by Steve West Breakdown of academic impact, for papers by Michael L. Lim Breakdown of academic impact, for papers by Gema González‐Pardo Breakdown of academic impact, for papers by Lloyd Curtis Breakdown of academic impact, for papers by Antonio Antela
Rankless by CCL
2026